Eptifibatide-induced profound thrombocytopaenia: A rare complication

Pranav Mahajan, Fatima Ayub, Roxana Azimi, Naveed Adoni

Research output: Contribution to journalArticlepeer-review


Drug-induced immune thrombocytopaenia (DITP) is a type of thrombocytopaenia caused by medications. It is one of the common causes of unexplained thrombocytopaenia. It is caused by the formation of autoantibodies against a particular drug and is commonly observed with medications like heparin and beta-lactam antibiotics. One of the rare causes of DITP is eptifibatide, a widely used antiplatelet agent for pretreatment in cardiac catheterisation. These patients can be asymptomatic or develop complications like skin bruising, epistaxis and even intracranial haemorrhage. We present a case of a 64-year-old man who developed eptifibatide-induced profound thrombocytopaenia leading to extensive skin bruising. He was treated with platelet transfusions followed by prompt improvement in platelet count. 2021 BMJ Publishing Group Limited. Published by BMJ.

Original languageEnglish (US)
Article numbere241594
JournalBMJ Case Reports
Issue number6
StatePublished - Jun 14 2021
Externally publishedYes


  • haematology (drugs and medicines)
  • interventional cardiology
  • unwanted effects/adverse reactions

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Eptifibatide-induced profound thrombocytopaenia: A rare complication'. Together they form a unique fingerprint.

Cite this